Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balinatunfib - Sanofi

Next Previous
Drug Profile

Balinatunfib - Sanofi

Alternative Names: SAR-441566

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Inflammation

Most Recent Events

  • 25 Mar 2025 Phase-II clinical trials in Ulcerative colitis (Treatment-experienced) in USA (PO) (NCT06867094) (EudraCT2025-520705-12)
  • 11 Dec 2024 Sanofi completes phase-II SPECIFI-PSO trials in Psoriasis in United Kingdom, Germany, Turkey, Spain, Portugal, Mauritius, Poland, Japan, Hungary, Georgia, Czech Republic, Czech Republic, China, Chile, Bulgaria, Canada, USA (PO) (NCT0607311)( EudraCT-2023-503911-14-00)
  • 10 Dec 2024 Phase-II clinical trials in Crohn's disease (Treatment-experienced) in USA, Australia (PO) (NCT06637631) (EUCT-2024-512633-32-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top